What this covers: Peptides studied for neuroprotection, BDNF expression, memory consolidation, focus, and anxiety reduction.
Test first: Establish a baseline including TSH, fasting insulin, vitamin D, hs-CRP, AM cortisol, and homocysteine.
Research focus: Russian nootropic peptides (Semax, Selank), NAD+ for neuronal energy, and Dihexa at the research frontier.
Key thing to know: Evidence varies by compound, from developed clinical literature (Semax, Selank) to earlier preclinical work (Dihexa); interpret with a licensed provider.
What does this goal involve?
Cognitive performance research in a peptide context spans several connected areas.
What it targets: Research here looks at compounds studied for neuronal health, synaptic plasticity, and the neurotransmitter systems behind focus, memory, and mood. Most evidence-supported compounds are primarily neuroprotective (preserving function) rather than neuroenhancing (raising it beyond baseline), with the clearest signals in people who have existing deficits, stress-related impairment, or age-related decline.
Common root causes: Research points to a few common, testable factors behind cognitive complaints in otherwise healthy people:
- Thyroid function — hypothyroidism can closely resemble cognitive decline (memory, brain fog, slowed processing) in the literature.
- Insulin resistance — impaired brain glucose use, sometimes described in research as “Type 3 diabetes.”
- Homocysteine — a modifiable factor with strong longitudinal data linking it to cognitive decline and dementia risk.
These are worth reviewing with a provider before nootropic peptide research.
Foundations first: Reviewing these first helps confirm cognitive symptoms are not driven by correctable nutritional or hormonal factors. When they are excluded, peptide research tends to focus on four distinct mechanisms:
- BDNF upregulation
- Neuroinflammation reduction
- Mitochondrial support for neuronal energy
- Neurotransmitter tone modulation
Biomarkers to establish before exploring this goal.
Research protocols for this goal area typically reference the following biomarkers as baseline context. Testing these first gives you and your healthcare provider the most relevant starting information.
Hypothyroidism can closely resemble cognitive decline — memory issues, brain fog, slowed processing, and mood changes. Worth reviewing with a provider before nootropic peptide research.
Impaired brain glucose use is studied in relation to cognitive aging. A useful baseline before nootropic peptide research.
Low vitamin D is associated with cognitive decline in longitudinal research. Vitamin D receptors are found throughout the brain, including the hippocampus.
A proxy for systemic inflammatory burden. Neuroinflammation is a key mechanism in cognitive aging, so a baseline helps frame anti-inflammatory research.
Sustained high cortisol is studied in relation to hippocampal stress, memory consolidation, and reduced BDNF expression. A helpful baseline when symptoms include anxiety, stress sensitivity, or poor memory under pressure.
One of the strongest modifiable nutritional risk factors for cognitive decline and dementia in longitudinal research. Studied as a neurovascular risk factor through mechanisms distinct from inflammation.
What does the research focus on for this goal?
Research for this goal concentrates on a few distinct compounds and pathways.
Semax and Selank: These have the most developed clinical literature here, largely from Russian research. Semax (an ACTH(4–10) analog) has been studied for BDNF expression and neuroprotection in stroke recovery and ischemia; Selank for anxiety, memory, and stress resilience via GABAergic, serotonergic, and BDNF-related mechanisms. Much of this evidence sits in Russian-language publications, which limits Western access.
NAD+: A metabolic angle on cognition, studied for its role in neuronal energy production, DNA repair, and sirtuin activation. Emerging human studies look at raising brain NAD+ through precursor supplementation, and NAD+ decline is an active topic in aging research — positioning it as both a longevity and a cognitive-performance compound.
Dihexa and MOTS-c: Dihexa is the research frontier: preclinical data show synaptogenesis and dendritic spine growth (the structural basis of memory), reportedly far beyond BDNF potency in some assays — but there is no published human trial data, so it warrants the highest caution. MOTS-c adds a metabolic angle through exercise-mimetic effects on neuronal insulin sensitivity and mitochondrial efficiency.
Peptides commonly researched for this goal.
The peptides below appear in research literature in connection with this goal. This is not a recommendation to use any of these compounds. Always consult a licensed healthcare provider.
ACTH(4–10) analog with Russian clinical data for neuroprotection and BDNF upregulation. Studied in stroke recovery, ischemic brain injury, and cognitive contexts, mostly in Eastern European research.
Anxiolytic peptide with clinical trial data on anxiety reduction, memory, and stress resilience via GABAergic and BDNF mechanisms. Studied as a non-sedating, non-dependence-forming option for stress-related cognitive impairment.
Metabolic cofactor studied for neuronal energy, DNA repair, and sirtuin activation. NAD+ decline is studied in relation to cognitive aging, with emerging human data on brain metabolic function.
Mitochondria-derived peptide with exercise-mimetic metabolic effects. Studied for neuronal insulin sensitivity and mitochondrial efficiency via AMPK activation, addressing the metabolic side of cognitive aging.
HGF modulator with preclinical data on synaptogenesis and dendritic spine density, reportedly far beyond BDNF potency. Notable for memory research, but the absence of published human trial data warrants the highest caution.
What research protocols typically examine.
Timeline
Cognitive research protocols typically run 4–8 weeks for subjective cognitive assessment using validated tools. Neuroinflammatory marker monitoring (hs-CRP, homocysteine) requires 8–12 weeks to show meaningful change. Structural changes (synaptic density) are assessed over months in preclinical studies.
Monitoring
TSH, fasting insulin, hs-CRP, homocysteine, Vitamin D, and AM cortisol at baseline and follow-up. Subjective cognitive function scores (MoCA, cognitive battery tools) as primary endpoints. Anxiety and stress measures (GAD-7, PSS) for anxiolytic peptide protocols.
Limitations
Cognitive function is highly subjective and confounded by sleep, hydration, stress, and motivation. Objective testing with validated batteries is essential for a meaningful research signal, and placebo response rates in cognitive studies are among the highest of any research category.